Understanding the role of Wee1 in gastrointestinal stromal tumors (GIST)
Official title: Elucidating the critical role of Wee1 in GIST
Funded at Research Inst of Fox Chase Can Ctr · NIH-11017070 · Data updated 2026-11-12
This study is looking at how a protein called Wee1 influences the growth of hard-to-treat gastrointestinal stromal tumors (GIST) in patients whose tumors no longer respond to standard therapies, with the hope of finding new treatment options that work better for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 1, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $430,050 |
| NIH project number | 5R01CA281212-03 |
| Project ID | NIH-11017070 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced gastrointestinal stromal tumors who have shown resistance to tyrosine kinase inhibitors.
✕Less likely to help
Patients with early-stage GIST or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates how the Wee1 protein affects the growth and treatment resistance of gastrointestinal stromal tumors (GIST). It focuses on patients with advanced GIST who have developed resistance to existing therapies. By using advanced techniques like kinome profiling and loss-of-function assays, the study aims to identify new treatment strategies that target Wee1 in combination with other therapies. The goal is to improve outcomes for patients whose tumors have become resistant to current treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with resistant GIST, potentially improving survival rates.
How similar studies have gone: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Rink, Lori — Research Inst of Fox Chase Can Ctr
- Study coordinator: Rink, Lori
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.